• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胸膜感染的诊断与管理

Diagnosis and management of pleural infection.

作者信息

Elsheikh Alguili, Bhatnagar Malvika, Rahman Najib M

机构信息

Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK.

出版信息

Breathe (Sheff). 2023 Dec;19(4):230146. doi: 10.1183/20734735.0146-2023. Epub 2024 Jan 16.

DOI:10.1183/20734735.0146-2023
PMID:38229682
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10790177/
Abstract

Pleural infection remains a medical challenge. Although closed tube drainage revolutionised treatment in the 19th century, pleural infection still poses a significant health burden with increasing incidence. Diagnosis presents challenges due to non-specific clinical presenting features. Imaging techniques such as chest radiographs, thoracic ultrasound and computed tomography scans aid diagnosis. Pleural fluid analysis, the gold standard, involves assessing gross appearance, biochemical markers and microbiology. Novel biomarkers such as suPAR (soluble urokinase plasminogen activator receptor) and PAI-1 (plasminogen activator inhibitor-1) show promise in diagnosis and prognosis, and microbiology demonstrates complex microbial diversity and is associated with outcomes. The management of pleural infection involves antibiotic therapy, chest drain insertion, intrapleural fibrinolytic therapy and surgery. Antibiotic therapy relies on empirical broad-spectrum antibiotics based on local policies, infection setting and resistance patterns. Chest drain insertion is the mainstay of management, and use of intrapleural fibrinolytics facilitates effective drainage. Surgical interventions such as video-assisted thoracoscopic surgery and decortication are considered in cases not responding to medical therapy. Risk stratification tools such as the RAPID (renal, age, purulence, infection source and dietary factors) score may help guide tailored management. The roles of other modalities such as local anaesthetic medical thoracoscopy and intrapleural antibiotics are debated. Ongoing research aims to improve outcomes by matching interventions with risk profile and to better understand the development of disease.

摘要

胸膜感染仍然是一个医学难题。尽管闭式引流在19世纪彻底改变了治疗方式,但随着发病率的上升,胸膜感染仍然带来了重大的健康负担。由于临床症状不具特异性,诊断存在挑战。胸部X光、胸腔超声和计算机断层扫描等成像技术有助于诊断。作为金标准的胸腔积液分析包括评估外观、生化标志物和微生物学。诸如可溶性尿激酶型纤溶酶原激活物受体(suPAR)和纤溶酶原激活物抑制剂-1(PAI-1)等新型生物标志物在诊断和预后方面显示出前景,微生物学显示出复杂的微生物多样性且与预后相关。胸膜感染的管理包括抗生素治疗、胸腔引流管置入、胸腔内纤维蛋白溶解疗法和手术。抗生素治疗依赖于根据当地政策、感染情况和耐药模式使用经验性广谱抗生素。胸腔引流管置入是主要的治疗手段,使用胸腔内纤维蛋白溶解剂有助于有效引流。对于药物治疗无反应的病例,可考虑电视辅助胸腔镜手术和胸膜剥脱术等外科干预措施。诸如RAPID(肾功能、年龄、脓性、感染源和饮食因素)评分等风险分层工具可能有助于指导个性化管理。局部麻醉下内科胸腔镜检查和胸腔内使用抗生素等其他方式的作用存在争议。正在进行的研究旨在通过使干预措施与风险状况相匹配来改善预后,并更好地了解疾病的发展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8b6/10790177/f9b5ff42a6c4/EDU-0146-2023.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8b6/10790177/58a83c6536aa/EDU-0146-2023.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8b6/10790177/f9b5ff42a6c4/EDU-0146-2023.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8b6/10790177/58a83c6536aa/EDU-0146-2023.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8b6/10790177/f9b5ff42a6c4/EDU-0146-2023.02.jpg

相似文献

1
Diagnosis and management of pleural infection.胸膜感染的诊断与管理
Breathe (Sheff). 2023 Dec;19(4):230146. doi: 10.1183/20734735.0146-2023. Epub 2024 Jan 16.
2
Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema.胸膜内纤维蛋白溶解疗法与安慰剂或不同的纤维蛋白溶解剂在治疗成人肺炎旁胸腔积液和脓胸中的比较。
Cochrane Database Syst Rev. 2019 Oct 30;2019(10):CD002312. doi: 10.1002/14651858.CD002312.pub4.
3
Intrapleural agents for pleural infection: fibrinolytics and beyond.胸腔内感染用药物:纤维蛋白溶解剂及其他。
Curr Opin Pulm Med. 2012 Jul;18(4):326-32. doi: 10.1097/MCP.0b013e3283531149.
4
Study protocol for DICE trial: Video-assisted thoracoscopic surgery decortication versus interventional radiology guided chest tube insertion for the management of empyema.DICE试验研究方案:电视辅助胸腔镜手术纤维板剥脱术与介入放射学引导下胸腔置管术治疗脓胸的对比研究
Contemp Clin Trials Commun. 2021 Apr 15;22:100777. doi: 10.1016/j.conctc.2021.100777. eCollection 2021 Jun.
5
Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions.胸腔液中 suPAR 水平可预测类肺炎性胸腔积液患者是否需要有创性治疗。
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1545-1553. doi: 10.1164/rccm.201911-2169OC.
6
Surgical versus non-surgical management for pleural empyema.胸腔积脓的手术治疗与非手术治疗
Cochrane Database Syst Rev. 2017 Mar 17;3(3):CD010651. doi: 10.1002/14651858.CD010651.pub2.
7
Drainage, fibrinolytics, or surgery: a comparison of treatment options in pediatric empyema.引流、纤维蛋白溶解剂或手术:小儿脓胸治疗方案的比较
J Pediatr Surg. 2004 Nov;39(11):1638-42. doi: 10.1016/j.jpedsurg.2004.07.015.
8
Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical Trial.胸腔内组织型纤溶酶原激活剂和脱氧核糖核酸酶α联合治疗与单独使用组织型纤溶酶原激活剂治疗儿童脓胸的疗效:一项随机临床试验。
JAMA Pediatr. 2020 Apr 1;174(4):332-340. doi: 10.1001/jamapediatrics.2019.5863.
9
Intrapleural fibrinolytics combined with image-guided chest tube drainage for pleural infection.胸膜内纤维蛋白溶解剂联合影像引导下胸腔闭式引流治疗胸膜感染。
Mayo Clin Proc. 2007 Apr;82(4):407-13. doi: 10.4065/82.4.407.
10
Management of parapneumonic effusions and empyema.肺炎旁胸腔积液和脓胸的管理
Semin Respir Crit Care Med. 2014 Dec;35(6):715-22. doi: 10.1055/s-0034-1395503. Epub 2014 Dec 2.

引用本文的文献

1
A Practical Approach to Pleural Infection.胸膜感染的实用治疗方法。
Pulm Ther. 2025 Jul 25. doi: 10.1007/s41030-025-00308-z.
2
Antimicrobial resistance and beta-lactamase gene distribution among clinical isolates: a two-year cohort study.临床分离株中的抗菌药物耐药性和β-内酰胺酶基因分布:一项为期两年的队列研究。
Sci Rep. 2025 Jul 4;15(1):23951. doi: 10.1038/s41598-025-08445-w.
3
Chest drainage or repeated thoracentesis for pleural infections: a clinical dilemma.胸腔引流或反复胸腔穿刺治疗胸膜感染:一个临床难题。

本文引用的文献

1
British Thoracic Society Guideline for pleural disease.英国胸科学会胸膜疾病指南。
Thorax. 2023 Jul;78(Suppl 3):s1-s42. doi: 10.1136/thorax-2022-219784.
2
The Short Long Antibiotic Course for Pleural Infection Management (SLIM) randomised controlled open-label trial.用于胸腔感染管理的短疗程与长疗程抗生素治疗(SLIM)随机对照开放标签试验。
ERJ Open Res. 2023 Apr 11;9(2). doi: 10.1183/23120541.00635-2022. eCollection 2023 Mar.
3
ERS/ESTS statement on the management of pleural infection in adults.欧洲呼吸学会/欧洲心胸外科学会关于成人胸膜感染管理的声明。
Pneumonia (Nathan). 2025 May 22;17(1):16. doi: 10.1186/s41479-025-00170-2.
4
Coexisting bilateral tracheal bronchi and accessory cardiac bronchus complicated with pneumonia and empyema: a case report.双侧气管支气管并存及副心支气管合并肺炎和脓胸:一例报告
J Med Case Rep. 2025 Apr 15;19(1):175. doi: 10.1186/s13256-025-05213-2.
5
Prognostic significance of pleural fluid microbiological positivity in pleural infection: a bicentric 10-year retrospective observational study.胸腔感染中胸腔积液微生物学阳性的预后意义:一项双中心10年回顾性观察研究
Respir Res. 2025 Feb 13;26(1):53. doi: 10.1186/s12931-025-03129-5.
6
Evaluating the feasibility, sensitivity, and specificity of next-generation molecular methods for pleural infection diagnosis.评估用于胸膜感染诊断的新一代分子方法的可行性、敏感性和特异性。
Microbiol Spectr. 2025 Feb 4;13(2):e0196024. doi: 10.1128/spectrum.01960-24. Epub 2025 Jan 15.
7
Chest Tubes and Pleural Drainage: History and Current Status in Pleural Disease Management.胸腔引流管与胸腔引流:胸膜疾病管理的历史与现状
J Clin Med. 2024 Oct 23;13(21):6331. doi: 10.3390/jcm13216331.
8
Infective Pleural Effusions-A Comprehensive Narrative Review Article.感染性胸腔积液——一篇综合性叙述性综述文章
Clin Pract. 2024 May 16;14(3):870-881. doi: 10.3390/clinpract14030068.
9
Diagnosing and managing pleural disease.诊断与处理胸膜疾病。
Breathe (Sheff). 2023 Dec;19(4):230230. doi: 10.1183/20734735.0230-2023. Epub 2023 Dec 19.
Eur Respir J. 2023 Feb 2;61(2). doi: 10.1183/13993003.01062-2022. Print 2023 Feb.
4
The Biological Role of Pleural Fluid PAI-1 and Sonographic Septations in Pleural Infection: Analysis of a Prospectively Collected Clinical Outcome Study.胸腔液 PAI-1 和超声分隔在胸腔感染中的生物学作用:一项前瞻性临床结局研究分析。
Am J Respir Crit Care Med. 2023 Mar 15;207(6):731-739. doi: 10.1164/rccm.202206-1084OC.
5
A feasibility randomised trial comparing therapeutic thoracentesis to chest tube insertion for the management of pleural infection: results from the ACTion trial.一项比较治疗性胸腔穿刺与胸腔置管引流治疗胸腔感染的可行性随机试验:ACTion 试验结果。
BMC Pulm Med. 2022 Aug 30;22(1):330. doi: 10.1186/s12890-022-02126-4.
6
Bleeding Risk With Combination Intrapleural Fibrinolytic and Enzyme Therapy in Pleural Infection: An International, Multicenter, Retrospective Cohort Study.胸腔感染中联合应用胸腔内纤维蛋白溶解酶和酶治疗的出血风险:一项国际性、多中心、回顾性队列研究。
Chest. 2022 Dec;162(6):1384-1392. doi: 10.1016/j.chest.2022.06.008. Epub 2022 Jun 16.
7
The bacteriology of pleural infection (TORPIDS): an exploratory metagenomics analysis through next generation sequencing.胸腔感染的细菌学(TORPIDS):通过下一代测序进行的探索性宏基因组分析。
Lancet Microbe. 2022 Apr;3(4):e294-e302. doi: 10.1016/S2666-5247(21)00327-X. Epub 2022 Mar 11.
8
Alteplase Dose Assessment for Pleural infection Therapy (ADAPT) Study-2: Use of 2.5 mg alteplase as a starting intrapleural dose.阿替普酶胸腔内感染治疗剂量评估(ADAPT)研究-2:使用 2.5mg 阿替普酶作为起始胸腔内剂量。
Respirology. 2022 Jul;27(7):510-516. doi: 10.1111/resp.14261. Epub 2022 Apr 19.
9
Steroid Therapy and Outcome of Parapneumonic Pleural Effusions (STOPPE): A Pilot Randomized Clinical Trial.类固醇治疗与类肺炎性胸腔积液的结局(STOPPE):一项初步随机临床试验
Am J Respir Crit Care Med. 2022 May 1;205(9):1093-1101. doi: 10.1164/rccm.202107-1600OC.
10
16S rRNA is a valuable tool in finding bacterial aetiology of community-acquired pleural empyema-a population-based observational study in South Sweden.16S核糖体RNA是确定社区获得性胸膜脓胸细菌病因的一项重要工具——瑞典南部一项基于人群的观察性研究
Infect Dis (Lond). 2022 Mar;54(3):163-169. doi: 10.1080/23744235.2021.1985165. Epub 2021 Oct 4.